Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.

Current cancer drug targets - 1 Jan 2014

Kanakkanthara Arun, Eras Jonathan, Northcote Peter T, Cabral Fernando, Miller John H

Abstract excerpt

Cancer cell lines selected for resistance to microtubule targeting agents (MTA) often have acquired mutations in the β-tubulin binding sites for these agents. Despite strong correlational evidence, the functional and quantitative significance of such mutations in the resistance to MTA remains unknown. We recently showed that peloruside A (PLA) and laulimalide (LAU)-resistant cancer cell lines, 1A9-R1 (R1) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Lactones

Share to Macrolides

Share to MutS Homolog 2 Protein

Share to Ovarian Neoplasms

Share to Tubulin

Source

Identifiers

PMID: 24245693
DOI: 10.2174/1568009613666131113101151

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.PMID 24245693Read ↗

Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.Semantic proximity Read ↗

βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.Semantic proximity Read ↗

βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.Semantic proximity Read ↗

Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.Semantic proximity Read ↗

Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.Semantic proximity Read ↗

Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.Semantic proximity Read ↗

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.Semantic proximity Read ↗

Characterizing the laulimalide-peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae.Semantic proximity Read ↗

Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical TrialsSemantic proximity Read ↗

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceSemantic proximity Read ↗

Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.Semantic proximity Read ↗

Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.